Atazanavir/ritonavir - Mylan LaboratoriesAlternative Names: Anzavir-R; Ritonavir/atazanavir
Latest Information Update: 21 Mar 2017
At a glance
- Originator Mylan Laboratories Limited
- Class Antiretrovirals
- Mechanism of Action HIV protease inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Marketed HIV infections
Most Recent Events
- 21 Mar 2017 Mylan's Atazanavir/ritonavir is still tentatively approved for HIV infections in USA (PO)
- 30 Jun 2012 Launched for HIV infections in India (PO)